PT  - JOURNAL ARTICLE
AU  - Vinall, Maria
ED  - Mease, Philip J.
TI  - 24-Week Results from the RAPID-PsA Study
DP  - 2012 Sep 01
TA  - MD Conference Express
PG  - 8--9
VI  - 12
IP  - 9
4099  - http://mdc.sagepub.com/content/12/9/8.2.short
4100  - http://mdc.sagepub.com/content/12/9/8.2.full
AB  - This article presents key results from the first Phase 3 trial of certolizumab pegol (CZP) in patients with active psoriatic arthritis (PsA). In the Phase 3, Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Subjects With Adult Onset Active and PsA study [RAPID-PsA; NCT01087788], patients who were treated with CZP were twice as likely to meet the primary study endpoint of ACR20 response at Week 12 compared with those who were taking placebo.